

DRUG NAME: Irinotecan**SYNONYM:** Irinotecan hydrochloride trihydrate, CPT-11**COMMON TRADE NAME(S):** CAMPTOSAR® (notice of compliance,¹ July 1997; patent expires² April 2005)**CLASSIFICATION:** Topoisomerase I inhibitor, cytotoxic*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Irinotecan is a semisynthetic, water-soluble derivative of camptothecin, which is a cytotoxic alkaloid extracted from plants such as *Camptotheca acuminata*.³ Irinotecan and its active metabolite, SN-38, inhibit the action of topoisomerase I, an enzyme that produces reversible single-strand breaks in DNA during DNA replication. These single-strand breaks relieve torsional strain and allow DNA replication to proceed. Irinotecan and SN-38 bind to the topoisomerase I-DNA complex and prevent religation of the DNA strand, resulting in double-strand DNA breakage and cell death. The precise contribution of SN-38 to the activity of irinotecan in humans is not known.⁴ Irinotecan is cell cycle phase-specific (S-phase).⁵

PHARMACOKINETICS:

Interpatient variability	high interpatient variability in the pharmacokinetics of irinotecan and SN-38	
Oral Absorption	rapidly absorbed; no information found on extent of absorption	
	time to peak plasma concentration	within 1-2 h ⁶
Distribution	detected in pleural fluid with maximum concentration of 37% for irinotecan and 76% for SN-38 of the corresponding plasma levels ⁷ ; also detected in sweat and saliva. ⁸	
	cross blood brain barrier?	no information found
	volume of distribution	125 mg/m ² dose: 110 ± 48.5 L/m ² ; 340 mg/m ² dose: 234 ± 69.6 L/m ²
	plasma protein binding	irinotecan: 30-68%; SN-38: 95%
Metabolism	primarily hepatic, rapidly converted to SN-38 by hepatic carboxylesterase enzymes; irinotecan and SN-38 undergo reversible, pH-dependent conversion between the active lactone (acidic pH) and inactive hydroxyacid (basic pH) forms. ⁴	
	active metabolite	SN-38
	inactive metabolite	SN-38 glucuronide, aminopentane carboxylic acid ⁷
Excretion	biliary and urinary excretion	
	bile ⁹	25% as irinotecan; 1% as SN-38
	urine	11-20% as irinotecan; < 1% as SN-38
	feces	63.7 ± 6.8% ¹⁰
	terminal half life	340 mg/m ² dose: irinotecan 11.7 ± 1.0 h; SN-38 21 ± 4.3 h half-life increases with dose but this does not affect the linear relationship between dose and AUC ¹¹
	clearance	13.3 ± 6.1 L/h/m ²
Gender	no clinically significant difference	
Elderly	no clinically significant difference	
Children	greater interpatient variability than in adults, with comparable clearance but shorter half-lives ^{12,13}	
Ethnicity	no information found	

Adapted from reference³ unless specified otherwise.

USES:**Primary uses:*** Colorectal cancer^{3,14-18}**Other uses:**

Cervical cancer¹⁹
 Esophageal cancer²⁰
 Gastric cancer²¹
 Glioma⁷
 Lung cancer^{22,23}
 Mesothelioma⁷
 Pancreatic cancer²⁴

* Health Canada Therapeutic Products Programme approved indication

Irinotecan is currently being studied in children.

SPECIAL PRECAUTIONS:

Prior radiation: Patients with previous pelvic or abdominal radiation have a greater risk of irinotecan-related toxicities and dose reduction is recommended.^{3,19} BCCA protocols recommend irinotecan not be used within six weeks of radiation, especially to the pelvis. Concurrent use of irinotecan as a radiation-sensitizing agent is under investigation.²⁵

Pulmonary syndrome: A potentially life-threatening syndrome consisting of dyspnea, fever, and reticulonodular pattern on chest x-ray occurred in some patients with pre-existing lung tumours or nonmalignant pulmonary diseases in early clinical trials. Although the extent to which irinotecan may have been responsible for this complication has not been established, caution is recommended.^{3,4}

Hyperbilirubinemia: The risk of severe (grade 3 or 4) neutropenia during the first course of irinotecan therapy may be substantially increased in patients with modest increase in serum bilirubin (17-35 µmol/L).³ The use of irinotecan in patients with significant hepatic dysfunction has not been established. In clinical trials, irinotecan was not administered to patients with serum bilirubin > 35 µmol/L, transaminase > 3 times the upper limit of normal (ULN) if no liver metastases, or transaminase > 5 times the ULN with liver metastases.⁴

Gilbert's syndrome: Individuals with Gilbert's syndrome have deficient uridine diphosphate glucuronosyltransferase activity, which is involved in the elimination of SN-38, the active metabolite of irinotecan. Hence, Gilbert's syndrome may increase the risk of irinotecan-induced toxicity.²⁶ Screening for Gilbert's syndrome using direct/indirect serum bilirubin is recommended.²⁷ Gilbert's syndrome is characterised by:

- consistent mild elevation of total serum bilirubin (20-90 µmol/L)
- indirect (unconjugated) bilirubin should be at least 90% by van den Bergh's test and 99% by high-performance liquid chromatography
- normal serum ALT and AST
- hemolysis excluded based on normal hemoglobin, haptoglobin and reticulocyte count²⁸

Carcinogenicity: There is some evidence linking therapy with topoisomerase I inhibitors, such as irinotecan, to the development of acute leukemias associated with specific chromosomal translocations.⁴

Mutagenicity: Irinotecan and its active metabolite SN-38 were not mutagenic in Ames test. However, irinotecan was clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.⁴

Fertility: No information found.

Pregnancy: FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (eg, if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).⁴

Breastfeeding is not recommended due to the potential secretion of irinotecan into breast milk.⁴

SIDE EFFECTS:

ORGAN SITE	SIDE EFFECT
<i>Clinically important side effects are in bold, italics</i>	
allergy/immunology	immunosuppressive ⁴

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
blood/bone marrow febrile neutropenia	anemia (61%, severe 7%)
	leukopenia (63%, severe 28%)
	neutropenia (54%, severe 26%) 125 mg/m ² weekly ²⁹ : nadir 15-27 days, recovery 23-35 days 350 mg/m ² 3-weekly ³⁰ : nadir 8-9 days, recovery 19-25 days
	neutropenic fever (3%)
	thrombocytopenia (7%, severe 3%) ³⁰
	thrombocytopenia, immune (rare) ³¹
cardiovascular (arrhythmia)	bradycardia (5%) ³²
cardiovascular (general)	edema (10%, severe 1%)
	hypotension (6%) ³²
constitutional symptoms	chills (14%, severe 0.3%)
	fatigue (76%, severe 12%)
	fever (45%, severe 0.7%)
	sweating (57%) ³²
	weight loss (30%, severe 0.7%)
dermatology/skin	<i>extravasation hazard: none</i> ³³
	alopecia (61%)
	flushing (11%, severe 0%)
	piloerection (3%) ³²
	rash (13%, severe 0.7%)
gastrointestinal	<i>emetogenic potential: high moderate</i> ^{29,34}
	abdominal enlargement (10%, severe 0.3%)
	anorexia (55%, severe 6%)
	constipation (30%, severe 2%)
	dehydration (15%, severe 4%)
	diarrhea, early onset (51%, severe 8%); see paragraph following Side Effects table
	diarrhea, late onset (88%, severe 31%); see paragraph following Side Effects table
	dyspepsia (11%, severe 0%)
	flatulence (12%, severe 0%)
	nausea (86%, severe 17%)
	salivation (11%) ³²
	stomatitis (12%, severe 0.7%)
	vomiting (67%, severe 13%)
hepatic	increased alkaline phosphatase (13%, severe 4%)
	increased AST (11%, severe 1%)
infection	minor infection (15%, severe 0%)
neurology	dizziness (15%, severe 0%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	insomnia (20%, severe 0%)
ocular/visual ³²	lacrimation (12%)
	miosis (10%)
	visual disturbances (15%)
pain	abdominal pain or cramping (57%, severe 16 %)
	back pain (15%, severe 2%)
	headache (17%, severe 0.7%)
	pain (24%, severe 2%)
pulmonary	cough (17%, severe 0.3%)
	dyspnea (22%, severe 4%)
	rhinitis (16%, severe 0%)
secondary malignancy	acute leukemias ⁴
syndromes	cholinergic syndrome
	pulmonary syndrome of dyspnea, fever and reticulonodular pattern on chest x-ray

Adapted from reference³ unless specified otherwise.

Early onset diarrhea and cholinergic syndrome: Irinotecan can cause both early and late onset diarrhea. Both forms of diarrhea may be severe and appear to be mediated by different mechanisms. Early onset diarrhea occurs during or within 24 hours of administration of irinotecan. It is usually transient and only infrequently severe. Early onset diarrhea is thought to be part of a cholinergic syndrome mediated by increased anticholinesterase activity of the irinotecan parent compound. It may be accompanied by other cholinergic symptoms such as rhinitis, hypersalivation, miosis, lacrimation, diaphoresis, flushing, and abdominal cramping. The cholinergic syndrome is more likely to occur at higher irinotecan dose levels and associated with the onset of peak irinotecan plasma levels.³ Thus, infusing irinotecan over less than 90 minutes may increase the likelihood of the cholinergic syndrome.³⁵ Early onset diarrhea and cholinergic symptoms are treated with atropine 0.3 – 0.6 mg IV or SC as needed, repeated up to a maximum dose of 1.2 mg. Blood pressure and heart rate should be monitored during atropine therapy.²⁷ Prophylactic atropine may be required for subsequent treatments.³⁰

Late onset diarrhea: This occurs more than 24 hours after administration of irinotecan and can be prolonged, leading to potentially life-threatening dehydration and electrolyte imbalance.³ The diarrhea has a median onset of 5 and 11 days after the 3-weekly³² and weekly³⁶ dosing schedule of irinotecan, respectively. The median duration of diarrhea for the one-weekly schedule was 3 days, with severe diarrhea (grades 3-4) lasting for 7 days.³ Late onset diarrhea is thought to be related to abnormal ion transport in the injured intestinal mucosa, leading to increased secretion of water and electrolytes into the intestinal lumen.³⁷ Management of diarrhea should include prompt treatment with high dose loperamide. Patients with severe diarrhea should be carefully monitored for dehydration and given fluid and electrolyte replacement as needed. Premedication with loperamide prior to irinotecan treatment is not required. However, patients should be instructed to have loperamide on hand and start the following treatment at the first poorly formed or loose stool, or earliest onset of more frequent bowel movement than usual (NB, loperamide dose used is higher than recommended by the manufacturer):

- loperamide 4 mg immediately
- then 2 mg every 2 hours until diarrhea-free for 12 hours
- may take 4 mg every 4 hours at night^{3,38}

An alternative regimen of loperamide 4 mg every 3 hours plus diphenhydramine 25 mg every 6 hours has also been used in a limited number of patients.¹⁴ Laxatives may increase the risk of severe diarrhea³ and patients should be counselled about laxative use during irinotecan treatment.

Severe liver enzyme abnormalities: Observed in less than 10% of patients, typically in those with known hepatic metastases.³

Insomnia and dizziness were not usually considered to be directly related to irinotecan in clinical trials. Dizziness may represent symptomatic orthostatic hypotension due to dehydration.³

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
anticonvulsants which induce cytochrome P450 (eg, carbamazepine, phenobarbital, phenytoin) ^{7,39}	may decrease therapeutic and toxic effects of irinotecan	increase irinotecan clearance via multiple mechanisms	may need to increase irinotecan dose for therapeutic effect
bevacizumab ⁴⁰	may increase toxic effects of irinotecan	unknown; increases plasma levels of irinotecan active metabolite (SN-38) by 33%	if patient develops severe diarrhea or neutropenia, decrease irinotecan dose as per protocol ^{41,42}
dexamethasone (chronic dosing) ⁷	may decrease therapeutic and toxic effects of irinotecan	increased irinotecan clearance via multiple mechanisms	may need to increase irinotecan dose for therapeutic effect
dexamethasone (antiemetic dosing) ⁷	unknown	effect of single-dose dexamethasone on irinotecan clearance is unknown	no clinical interventions appear necessary
docetaxel ⁴³	no pharmacokinetic interactions observed		
etoposide ⁴⁴	hepatotoxicity	unknown	avoid concurrent use
lopinavir-ritonavir ^{45,46} ; see paragraph following table	increased toxic effects of irinotecan	decreased clearance of irinotecan metabolites due to CYP3A4 and UGT1A1 inhibition	avoid concurrent use of HIV protease inhibitors with irinotecan
prochlorperazine ³	increased incidence of akathisia (on weekly schedule)	unknown	avoid on day of irinotecan treatment
St. John's wort ⁴⁷	reduced therapeutic and toxic effects of irinotecan	inhibited CYP3A4 metabolism of irinotecan, leading to decreased plasma levels of the active metabolite (SN-38)	avoid concurrent use

Multiple mechanisms have been suggested to contribute to drug interactions. As irinotecan and its active metabolite SN-38 are oxidized by CYP3A4 to two relatively inactive metabolites, most interactions are attributed to inhibition or induction of this enzyme. Coadministration with CYP3A4 inhibitors can potentially lead to significantly increased formation of SN-38 and result in toxicity. Coadministration with CYP3A4 inducers leads to a reduction in SN-38 plasma levels, which may have a deleterious effect on treatment outcome. Other suggested mechanisms for drug interactions include: induction/inhibition of carboxyl esterase, UGT1A1, and drug transporters.⁴⁸

HIV protease inhibitors. Inhibition of UGT1A1 may interfere with the metabolism of SN-38, an active metabolite of irinotecan, resulting in increased irinotecan-related toxicities. *In vitro* studies in humans have shown that human UGT1A1 was inhibited by several HIV protease inhibitors, with atazanavir exhibiting the greatest inhibitory activity. Additionally, irinotecan is oxidized directly to an inactive metabolite via the CYP3A4 pathway, another pathway inhibited by HIV protease inhibitors. Based on this evidence, it is generally suggested that coadministration of irinotecan and all HIV protease inhibitors should be avoided,^{45,46,48} and that in company literature, coadministration of irinotecan with atazanavir is specifically contraindicated.⁴⁹

SUPPLY AND STORAGE:

Injection:

Pfizer Canada Inc. supplies irinotecan as single use vials (40 mg, 100 mg, and 300mg) in a concentration of 20 mg/mL. Store at room temperature. Protect from light.⁴⁸

Novopharm Limited supplies irinotecan as latex-free single use vials (40 mg and 300 mg) in a concentration of 20 mg/mL. Store at room temperature. Protect from light.⁵⁰

Hospira Healthcare Corporation supplies irinotecan as single use vials (40 mg, 100 mg and 500 mg) in a concentration of 20 mg/mL. Store at room temperature. Protect from light.⁵¹
 Sandoz Canada Inc. supplies irinotecan as latex-free single use vials (40 mg and 100 mg) in a concentration of 20 mg/mL. Store at room temperature. Protect from light.⁵²

For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.

Additional information:

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BCCA administration guideline in ***bold, italics***

Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	no information found
<i>Intermittent infusion</i>	<i>in 500 mL D5W over 90 min</i> has also been given over 30-60 min ^{8,19,20}
Continuous infusion	investigational, has been used in clinical trials at lower dosage (12.5 mg/m ² /day) over 96 h ⁵³
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BCCA usual dose noted in ***bold, italics***

<i>Intravenous:</i>	Cycle Length:	
	<i>3 weeks:</i>	<i>350 mg/m²</i> (range 200-350 mg/m ²) <i>IV for one dose on day 1</i> <i>maximum single dose: 700 mg^{3,4,27}</i>
	4 weeks ²³ :	60 mg/m ² IV for one dose on days 1, 8 and 15 (total dose per cycle 180 mg/m ²)
	<i>6 weeks:</i>	<i>125 mg/m²</i> (range 50-150 mg/m ²) <i>IV for one dose on days²³</i> <i>1, 8, 15 and 22</i> <i>(total dose per cycle 500 mg/m²</i> [range 200-600 mg/m ²]) NB, sometimes referred to as the "weekly schedule"
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"	

<i>Dosage in renal failure:</i>	no adjustment required ³	
<i>Dosage in hepatic failure:</i>	3 weeks:	consider lower starting dose for patients with a combined history of prior pelvic/abdominal radiation and modestly elevated total serum bilirubin (17-35 µmol/L) ^{3,4}
	4 weeks:	consider lower starting dose for patients with a combined history of prior pelvic/abdominal radiation and modestly elevated total bilirubin (17-35 µmol/L) ⁴
	6 weeks:	consider lower starting dose (eg, 100 mg/m ² IV) for patients with a combined history of prior pelvic/abdominal radiation and modestly elevated total bilirubin (17-35 µmol/L) ⁴
	irinotecan has not been studied in patients with total bilirubin > 35 µmol/L, transaminase > 3 times the upper limit of normal (ULN) if no liver metastases, or transaminase > 5 times the ULN with liver metastases. ⁴	
<i>Dosage in Gilbert's syndrome:</i>	3 weeks:	reduce the starting dose ³ to 200 mg/m ²
	4 weeks:	no information found
	6 weeks:	no information found
<i>Dosage in dialysis:</i>	no information found	

*Dosage in diarrhea*²⁶:

NCIC Grade (value)	During therapy	Start of next course	
	4 and 6 week cycles	4 and 6 week cycles	3 week cycle
1 (2-3 stools/day more*)	maintain dose level	maintain dose level	maintain dose level
2 (4-6 stools/day more*)	reduce by 25 mg/m ²	maintain dose level	maintain dose level
3 (7-9 stools/day more*)	omit dose, then reduce by 25 mg/m ² when resolved to ≤ grade 2	reduce by 25 mg/m ²	reduce by 50 mg/m ²
4 (≥ 10 stools/day more*)	omit dose, then reduce by 50 mg/m ² when resolved to ≤ grade 2	reduce by 50 mg/m ²	reduce by 50 mg/m ²

*more than pre-treatment

Children:

Irinotecan is currently being studied in children.

REFERENCES:

- Health Canada Therapeutic Products Programme. Notices of compliance (NOC)-Drugs. Available at: <http://www.hc-sc.gc.ca/hpb-dgps/therapeutic/htmleng/noc-drugs.html>. Accessed July 11, 2000.
- Health Canada Therapeutic Products Programme. Patent register. Available at: <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/patents.html>. Accessed June 16, 2000.
- Pharmacia and Upjohn. Camptosar product monograph. Mississauga, Ontario; 26 August 1999.
- Irinotecan. USP DI. Volume 1. Drug information for the health care professional. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2000.
- Rothenberg ML, Kuhn JG, Schaaf LJ, et al. Alternative dosing schedules for irinotecan. *Oncology (Huntington)* 1998;12(8 Suppl 6):68-71.
- Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. *Journal of Clinical Oncology* 1999;17(2):685-96.
- Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. *Journal of Clinical Oncology* 1999;17(5):1516-25.
- Abigeres D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. *Journal of Clinical Oncology* 1995;13(1):210-21.
- Chabot GG. Clinical pharmacokinetics of irinotecan. *Clinical Pharmacokinetics* 1997;33(4):245-59.
- Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 2000;28(4):423-33.

11. Chabot GG, Abigeres D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. *Annals of Oncology* 1995;6(2):141-51.
12. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. *Clinical Cancer Research* 2000;6(3):813-9.
13. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. *Cancer Research* 1994;54(2):427-36.
14. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. *Journal of Clinical Oncology* 1996;14(3):709-15.
15. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. *Journal of Clinical Oncology* 1996;14(4):1128-35.
16. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. *Journal of Clinical Oncology* 1997;15(8):2910-9.
17. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. *Seminars in Oncology* 1999;26(1 Suppl 5):6-12.
18. Van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. *Seminars in Oncology* 1999;26(1 Suppl 5):13-20.
19. Lhomme C, Fumoleau P, Fargeot P, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. *Journal of Clinical Oncology* 1999;17(10):3136-42.
20. Ison DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. *Journal of Clinical Oncology* 1999;17(10):3270-5.
21. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. *Journal of Clinical Oncology* 1999;17(1):319-23.
22. DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. *Journal of Clinical Oncology* 1999;17(9):2710-20.
23. Noda K, Nishiwaki Y, Kawahara M, et al. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive- disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511). *Proceedings of the American Society of Clinical Oncology* 2000;19:483a (abstract 1887).
24. Rocha Lima C, Svarese D, Bruckner H, et al. Multicenter phase II Trial of first-line irinotecan and gemcitabine (Irinogem) in patients with locally advanced or metastatic pancreatic cancer. *Proceedings of the American Society of Clinical Oncology* 2000;19:263a (abstract 1023).
25. Rich TA, Kirichenko AV. Camptothecin radiation sensitization: mechanisms, schedules, and timing. *Oncology (Huntington)* 1998;12(8 Suppl 6):114-20.
26. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. *Annals of Oncology* 1997;8(10):1049-51.
27. B.C. Cancer Agency Gastrointestinal Tumour Group. BCCA protocol summary for second-line palliative treatment for fluorouracil-refractory metastatic colorectal cancer using irinotecan (GIIR). Vancouver, British Columbia: BC Cancer Agency; 1 December 2000.
28. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *New England Journal of Medicine* 1995;333(18):1171-5.
29. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. *Journal of Clinical Oncology* 1993;11(5):909-13.
30. Cersosimo RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. *Annals of Pharmacotherapy* 1998;32(12):1324-33.
31. Bozec L, Bierling P, Fromont P, et al. Irinotecan-induced immune thrombocytopenia. *Annals of Oncology* 1998;9(4):453-5.
32. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. *Journal of Clinical Oncology* 1997;15(1):251-60.
33. Berg D. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. *Oncology Nursing Forum* 1998;25(3):535-43.
34. Anonymous. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. *Am J Health Syst Pharm* 1999;56(8):729-764.
35. McEvoy GK, editor. AHFS 2000 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.
36. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. *Proceedings of the American Society of Clinical Oncology* 1997;16:228a (abstract 803).
37. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. *Journal of Clinical Oncology* 1998;16(8):2745-51.
38. Abigeres D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. *Journal of the National Cancer Institute* 1994;86(6):446-9.
39. Reid JM, Buckner JC, Schaaf LJ, et al. Anticonvulsants Alter the Pharmacokinetics of Irinotecan (CPT-11) in Patients with Recurrent Glioma. *Proceedings of the American Society of Clinical Oncology* 2000;19:160a (abstract 620).
40. Hoffmann-La Roche Limited. AVASTIN® product monograph. Mississauga, Ontario; 9 September 2005.
41. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine. Vancouver: BC Cancer Agency; 2006.
42. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Folinic Acid (Leucovorin) and Bevacizumab. Vancouver: BC Cancer Agency; 2006.
43. Ford HE, Cunningham D, Ross PJ, et al. Phase I study of irinotecan and raltitrexid in patients with advanced gastrointestinal tract adenocarcinoma. *British Journal of Cancer* 2000;83(2):146-52.

44. Ohtsu T, Sasaki Y, Igarashi T, et al. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. *Japanese Journal of Clinical Oncology* 1998;28(8):502-6.
45. Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. *Clin Pharm Ther* 2008;83(4):601-606.
46. Drug Interaction Facts (database on the Internet). Irinotecan. Facts and Comparisons 4.0, 2010. Available at: <http://online.factsandcomparisons.com>. Accessed 24 February 2010.
47. Mathijssen RHJ, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. *JNCI Cancer Spectrum* 2002;94(16):1247-1249.
48. Pfizer Canada Inc. CAMPTOSAR® product monograph. Kirkland, Quebec; 29 June 2009.
49. Bristol-Myers Squibb Canada. REYATAZ® product monograph. Montreal, Quebec; 6 November 2009.
50. Novopharm Limited. Irinotecan for injection® product monograph. Toronto, Ontario; 11 June 2008.
51. Hospira Healthcare Corporation. Irinotecan hydrochloride trihydrate for injection® product monograph. Saint-Laurent, Quebec; 20 April 2009.
52. Sandoz Canada Inc. Irinotecan hydrochloride trihydrate injection® product monograph. Boucherville, Quebec; 25 January 2008.
53. Takimoto CH, Morrison G, Harold N, et al. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. *Journal of Clinical Oncology* 2000;18(3):659-67.